Medicenna Therapeutics Corp.
No enriched coverage for $MDNAF in the last 7 days.
No SEC Form 4 filings for $MDNAF in the last 30 days.
See all $MDNAF insider activity →Medicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.
Medicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.
AlphAI scores every news story that mentions MDNAF with an AI model for sentiment and relevance, and aggregates insider trades from Medicenna Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.
1 min read
